Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Vermillion — Investor Presentation (January 2017)
36 slides from Aspira Women's Health's investor presentation, Jan 6, 2017
Slide 1: Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes
(J VERMILLION’ Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes y eee Tee Tee — PIA. LABS . ‘. y 2 ee NASDAQ: VRML ’ a NA _* JANUARY 2017 ¢ _. wo " 4 al » : A ® mi i" ar ZY ASPIRA
Slide 2: Forward-Looking Statements
42 VERMILLION’ FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “wi
Slide 3: Company Overview
Company Overview e Ticker Symbol: VRML (NASDAO CM) ¢ Market Cap (12-27-2016): $52.8M - Shares Outstanding (10-31-2016): 52.3M e Cash and Cash Equivalents (9-30-2016): $8.1M e Enterprise Value: $46.6M QVERMILLION' — 62017 Vermilion ine Al Rights Reserved 3
Slide 4: Vermillion's Focus is Gynecologic Health
Vermillion’s Focus is Gynecologic Health Our Vision To be the global diagnostic platform leader in advancing women’s health with information and technologies to improve outcomes! Our Mission To allow women with pelvic pain and masses to have painless and disease free lives! Logistics Partner F a Col
Slide 5: Investment Highlights
Investment Highlights ¢ Target market expanding to > $1 billion with the OVA family of products* ¢ Key investor support from Jack W. Schuler and Oracle Investment Management 2015: e August: Al] OVA1 testing migrated from Quest Diagnostics to ASPiRA Labs © December: Published OVA1 cost effectiveness
Slide 6: Vermillion Has a Large Market Opportunity
Vermillion Has a Large Market Opportunity Benign US healthcare system annually Mass °2"°° Non-Gyn spends $22B on endometriosis ssqice Mass i 5 Physiologic care', $5.1B on Ov Ca care? and Cyst $1.2B on PCOS care? 100K - 300K® 2 75-90% benign® Ovarian : Pelvic : Pelvic : Pelvic Cancer : Masses : Masse
Slide 7: Ovarian Cancer - The Size of the Problem
Ovarian Cancer - The Size of the Problem Ovarian cancer stage at presentation and survival 5-Year F sue | onion [inte St, (2 VERMILLION" Stagel [eee to the ovary on Extends to true pelvis Stage Il | Extends beyond the true pelvis Stage IV Distant disease 23% 13% 47% 16% 90% 80% 15-20% <5% >60% of ov
Slide 8: Despite This Unmet Clinical Need...
Despite This Unmet Clinical Need... ..-no solution exists. Current standard of care is inadequate to manage patients and results in poor outcomes and increased costs 41. Current clinical assessment is inadequate e Physical exam is specialist-dependent ¢ Imaging is subjective 2. CA-125 is used off-la
Slide 9: Vermillion's Solution - 1st Generation
Vermillion’s Solution - 1st Generation a MIA (Multi-Variate Index Assay) FDA-cleared liquid biopsy test, which pre-operatively assesses risk of ovarian cancer and helps triage high risk patients The OvaCalc® algorithm combines five biomarker results into a single numerical “test value” related to th
Slide 10: Vermillion's Solution - 2nd Generation
Vermillion’s Solution - 2nd Generation Overa (MIA2G) Confidence FDA-cleared liquid biopsy test, which pre-operatively assesses risk of ovarian cancer and helps triage high risk patients The OvaCale® algorithm combines five biomarker results into a single numerical “test value” related to the probabi
Slide 11: 85% Reduction
85% Reduction Vv 31% Bu 37% 50% Rate of Cancer DETECTED I Rate of Cancer MISSED 0% CA125-I* CA125-Il+ Modified OVA1 OVA1 + Clinical ~~ ACOG** Clinical * Assessment Assessmentt (n= 1016 surgeries, with 86 early stage cases, 61 Stage I, 25 Stage Il) Clinical Impression included physician physical exam
Slide 12: Key Publications
Key Publications QQ VERMILLION" Title Author, Institution Effectiveness of multivariate index assay in University the preoperative of Kentucky ‘assessment of ovarian (Ovarian malignancy risk stratification of the Bristow, adnexal mass using etal. multivariate index. UC Irvine assay Clinical performa
Slide 13: Vermillion's Solution: How It is Used in Practice
Vermillion’s Solution: How It is Used in Practice e It may take Annual 7-9 months Survey from initial Physical Exam and History symptoms to ovarian TV US for Pelvic Mass cancer diagnosis! © 2/3 ovarian Pre-surgical Assessment cancer patients today are not optimally managed by a specialist? Observe,
Slide 14: OVA1/Overa vs Standard of Care
OVA1/Overa”™ vs Standard of Care CA-125t ROMA Stage | Stage Il Stage Ill Stage IV Sensitivity Across Menopausal Status* Pre-menopausal Post-menopausal Sensitivity Across Histological Subtypes* Epithelial ovarian cancer Non-epithelial cancer Low malignant potential Metastatic NNN NSN SENN SNS v v v v
Slide 15: New OVA1 Plus Report
New OVA1 Plus Report > ASPIRA LABS “= Ove? Pelvic Mass Risk Assessment ‘Accession No: AZOOI277 lent No: Test OB: ovo1/1900 Age: 116 Sex: FEMALE ‘Final Report Date; DRAFT Date specimen Collected: 1110272016 UNK Released By: Date Specimen Recsived: 11272016 1042 Menopausal Status: Post-Menopausal TEST
Slide 16: Publications Drive Standard of Care/Reimbursement
Publications Drive Standard of Care/Reimbursement Published Evidence Ueland, et al. Obstetrics and Gynecology, 2011 Bristow, et al. Gynecologic Oncology, 2013 Am J Gynecol, 2013 Longoria, et al. Am J Obstet Gynecol, 2013 Goodrich, et al. Am J Obstet Gynecol, 2015 Forde, et al. Curr Med Res Opin. 201
Slide 17: Intellectual Property
Intellectual Property Strong IP Protection ear seen Fa] er [ao] 11 [35 [as ¢ Issued patents covering various ovarian cancer biomarkers e Pending patent applications covering OVA1® and Overa™ products e Algorithm - kept as trade secret QVERMILLION' ©2017 Vermilion nc Al gh Reser .
Slide 18: Overa - Breakthrough in Ovarian Cancer Management
Overa”™ - Breakthrough in Ovarian Cancer Management |_| Sensitivity | Specificity OVA1" 92% 54% 31% 97% (9526CI) (85.1-96.3) (48.6-58.3) (26.0-37.0) (93.6—98.5) Standalone Risk Stratification Veracyte? Afirma 92% 52% 32-47% 93-96% GEC Overa ° 0, (95%Cl) 92% 97% 1. Bristow Ri 2. Alexander EK, et 2015
Slide 19: We Save More Lives and Reduce More Cost
We Save More Lives and Reduce More Cost By Evolving Our Strategy with Overa”™ To radically improve patient care, we have expanded our scope by classifying all pelvic mass patients to determine the best disease management care path 500K to 1M pelvic masses diagnosed’ Correct referral for Correct trea
Slide 20: Algorithm Platform
Algorithm Platform 4 Impact more than 1M patients' A platform that can be commercially replicated 5) 1. Company estimates
Slide 21: Product Pipeline of ASPiRA Labs
Product Pipeline of ASPiRA Labs k<— 2016 2017 2018 2019 2020 VA1/Overa | OVA1/O: plus 1. plus 2. Previous, plus Correct Correct Rule-out, surgical Rule-out, surgical Previous, plus Proposition specialist specialist pathway choice, pathway choice, diferente differential Dx referral referral progressi
Slide 22: Overall Total
OVERALL TOTAL 2.2B - $4.4B US 250K - 1M TAM EX US 2.5M - 10M TAM Rule out; watchful waiting, surgical US $440M = $880M choice, disease progression, EX US $500M-$1 B recurrence monitoring US 100K - 300K TAM US $67M . $200M ccc a EX US $100M-$300M All TAM and revenue numbers according to Company estim
Slide 23: The Value of Vermillion's Solution for all Customers
The Value of Vermillion’s Solution for all Customers ¢ Improve time to Tx To Patients ¢ Low risk: peace of mind ¢ High risk: get to the right specialist e Improved differential Dx ° Low risk: keep patient To Providers fecal To Payers mE _QVERM ILLION" ©2017 Vermilion ne. All Rights Reserved re ¢ Hig
Slide 24: U.S. International
U.S. INTERNATIONAL Top down, high-touch approach to IDNs, systems, ACOs Bottom up low-touch approach to patients, providers es _ WVDService Offering —$= *Overa (TM) Platform: Roche cobas 4000, 6000, 8000 https://usdiagnostics.roche.com/en/core_laboratory/analyzers.html 90% of Ov Ca occurs ex-U.S. Ov
Slide 25: Commercialization Strategy
Commercialization Strate Payer strategy to increase utilization and drive price based on HECON Mi th KOL strategy in hospital yn eee te systems and regional lab drive volume in ASPiRA Labs ¥ 9) 5 contracts to drive care referral base (Testing and patient data) pathways Hospital Systems / Regional La
Slide 26: OVA1 Coverage YTD - Patient Lives in Millions
OVA1® Coverage YTD - Patient Lives in Millions Goal: Targeted Growth with Positive Medical Policy Decisions Target: National Payer 80M. © rm ay is] ma Louisiana Sarehirs’ Arkansas Michigan 60M (€ Meare Novitas 6/2014 12/2015 _QVERM ILLION® ©2017 Vermilion inc. All Rights Reserved 26
Slide 27: Clinical Utility Publication
Clinical Utility Publication* @ 22 physicians with =>5 OVAT1 results ¢ 136 OVA1-positive cases scored ¢ 122 Surgeries resulted from these -42 benign tumors ¢ Purpose: To assess OVA1's ability to drive referral of ovarian cancer patients to GYN ONC prior to their first surgical intervention ¢ Method:
Slide 28: Cost Effectiveness Model Analysis
Cost Effectiveness Model Analysis ICER OVA1* ASPiRA ~$1,495 $12,189/QALY' OVA1** ASPiRA ~$1,495 $35,094/OALY' BRCA1/2 Myriad Genetics ~$4,040 $36,845/QALY Oncotype DX Genomic Health ~$4,175 $15,578/QALY? Considered cost effective when under threshold $50,000/QALY * Use of OVA1 resulted in fewer proj
Slide 29: Experienced Management Team in Place
Experienced Management Team in Place Experience Valerio Palmieri President and CEO DIANON Systems _ LabCorp SaiepCereay Pen Creencines Marra S. Francis, MD, FACOG Chief Medical Officer yriag Wag) Chr = Fredicerrars Chief Operating Officer A ORA xLabCorp DIAGNOSTICS ‘Abo Corosry DE sec nema vine SVP,
Slide 30: 2015-2016 Achievements / 2017 Anticipated
2015-2016 Achievements / 2017 Anticipated 2015 y Strategic partnership study with Kaiser Permanente (So. CA) announced v¥ Conversion of OVA1 volume from Quest Diagnostics to ASPIRA Labs Vv Publish OVA1 cost effectiveness data 2016 V Overa FDA Clearance v Announce international distribution partnersh
Slide 31: Current Financial Priorities
Current Financial Priorities e Price (maintain / build value) e Sales ramp / penetration (build on existing market share / call point) e Margins (>80% over 2016 - 2019) e Reimbursement - revenue cycle management e Generate margin through ASPiRA IVD _QVERM ILLION® ©2017 Vermillion inc. All Rights Res
Slide 32: Vermillion Expects to Be a Market Leader by 2020
Vermillion Expects to Be a Market Leader by 2020 - Anticipated Milestones Volume multipliers - + Sales/Regional lab strategy Direct to ‘Consumer/DTW ——- — OVA1/Overa Launched plus 2.0 Mar 2016 Symptom OVAI + 1.0 VAI Ovsta Launched Nov “inicalutliy/ 2016 NCCN, ACOG Guidelines || OV SACOG guidelines D
Slide 33: Sustainable Advantages, Tailwinds and Headwinds
Sustainable Advantages, Tailwinds and Headwinds Sustainable Advantages ¢ Biomarker IP ¢ Trade secret algorithm e ASPiRA Labs data structure and source | Tailwinds , “ e FDA and LDT process experience ¢ Robust clinical / health economics publication pipeline ¢ World-class clinical partners Headwinds
Slide 34: Vermillion's Strategy: Built for the Future
Vermillion’s Strategy: Built for the Future Strategic Strengths and Capabilities Gx Health foeee FDA-cleared product Unique Category 1 CPT code (AMA) Medicare Coverage/Gap Fill Pricing IVD kit CLIA lab for LDTs Multi-modal predictive analytics Proprietary disease registry/samples Leading peer-review
Slide 35: Conclusions
Conclusions Y First of its kind, FDA-cleared multi-variate global technology platform Y In two pivotal trials, OVA1® detected >80% cancers missed by CA125 and physician assessment!” Y 2016 Progress ¢ 2nd Generation product (Overa) FDA Cleared - 30% improvement in specificity e November 2016, ACOG Gu
Slide 36: Vermillion Contact Information
(Y VERMILLION’ www.vermillion.com (QVERMILLION® ©2017 Vermilion inc. All Rights Reserved Corporate Headquarters 12117 Bee Caves Rd. Building III, Suite 100 Austin, TX 78738 Tel: 512.519.0400 Fax: 512.439.6980 ASPiRA IVD 35 Nutmeg Dr. Suite 260 Trumbull, CT 06611 Tel: 203.993.8294 Fax: 203.502.8689 I